Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1992 Oct;68(4):387–391. doi: 10.1136/hrt.68.10.387

Increased circulating atrial natriuretic factor concentrations in patients with chronic heart failure after inhibition of neutral endopeptidase: effects on diastolic function

David B Northridge 1,2,3, Alan Jardine 1,2,3, Esther Henderson 1,2,3, Stephen G Dilly 1,2,3, Henry J Dargie 1,2,3
PMCID: PMC1025138  PMID: 1449922

Abstract

Objective—±Candoxatrilat was used to raise atrial natriuretic factor (ANF) concentrations in patients with heart failure, and the effects on left ventricular systolic and diastolic function were studied to determine the contribution of peripheral and central mechanisms to the haemodynamic effects.

Design—This was a single blind, randomised comparison of ±candoxatrilat and placebo in patients with mild heart failure. All patients received two intravenous doses of ±candoxatrilat and two placebo doses on four consecutive days.

Setting—A teaching hospital department of cardiology.

Patients—Six men (mean age 52 years) with mild heart failure (New York Heart Association class II) due to ischaemic heart disease (four patients) or dilated cardiomyopathy (two patients) were included. Mean ejection fraction was 37·5% and mean peak oxygen consumption was 20·4 ml/min/kg.

Main outcome measures—Plasma ANF concentrations, haemodynamic indices and left ventricular diastolic function measured by early to atrial filling rate (E:A ratio) with Doppler echocardiography were determined before and after ±candoxatrilat and placebo.

Results—±Candoxatrilat caused a threefold rise of plasma ANF compared with placebo (p < 0·005), but there was no significant change in heart rate, blood pressure, or cardiac output. Mean right atrial pressure fell from 6·7 to 4·7 mm Hg (NS) and pulmonary artery wedge pressure fell from 9·2 to 6·7 mm Hg (p < 0·05). Doppler echocardiographic measurements of transmitral blood flow showed a significant fall in peak early left ventricular filling velocity from 39·5 to 34·2 cm/s (p < 0·05), along with a non-significant rise in peak atrial filling velocity from 39·7–41·6 cm/s after ±candoxatrilat. The E:A ratio, a Doppler index of left ventricular diastolic function, fell from a mean of 1·04 to 0·87 (p < 0·05).

Conclusions—±Candoxatrilat increased plasma ANF concentrations and reduced right atrial and pulmonary artery wedge pressures. No evidence of an improvement in left ventricular systolic or diastolic function was found, so the fall in preload was due to peripheral effects, either an increase in venous capacitance or a fall in circulating blood volume.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cody R. J., Atlas S. A., Laragh J. H., Kubo S. H., Covit A. B., Ryman K. S., Shaknovich A., Pondolfino K., Clark M., Camargo M. J. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest. 1986 Nov;78(5):1362–1374. doi: 10.1172/JCI112723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Crozier I. G., Nicholls M. G., Ikram H., Espiner E. A., Gomez H. J., Warner N. J. Haemodynamic effects of atrial peptide infusion in heart failure. Lancet. 1986 Nov 29;2(8518):1242–1245. doi: 10.1016/s0140-6736(86)92675-9. [DOI] [PubMed] [Google Scholar]
  3. Faber J. E., Gettes D. R., Gianturco D. P. Microvascular effects of atrial natriuretic factor: interaction with alpha 1- and alpha 2-adrenoceptors. Circ Res. 1988 Aug;63(2):415–428. doi: 10.1161/01.res.63.2.415. [DOI] [PubMed] [Google Scholar]
  4. Friedman B. J., Plehn J. F. Noninvasive analysis of ventricular diastolic performance: in quest of a clinical tool. J Am Coll Cardiol. 1988 Oct;12(4):944–946. doi: 10.1016/0735-1097(88)90459-7. [DOI] [PubMed] [Google Scholar]
  5. Herrmann H. C., Palacios I. F., Dec G. W., Scheer J. M., Fifer M. A. Effects of atrial natriuretic factor on coronary hemodynamics and myocardial energetics in patients with heart failure. Am Heart J. 1988 Jun;115(6):1232–1238. doi: 10.1016/0002-8703(88)90014-2. [DOI] [PubMed] [Google Scholar]
  6. Hughes A., Thom S., Goldberg P., Martin G., Sever P. Direct effect of alpha-human atrial natriuretic peptide on human vasculature in vivo and in vitro. Clin Sci (Lond) 1988 Feb;74(2):207–211. doi: 10.1042/cs0740207. [DOI] [PubMed] [Google Scholar]
  7. Jardine A. G., Connell J. M., Northridge D., Dilly S. G., Cussans N. J., Davidson G., Doyle J., Leckie B. L., Lever A. F. The atriopeptidase inhibitor UK 69,578 increases atrial natriuretic factor and causes a natriuresis in normal humans. Am J Hypertens. 1990 Sep;3(9):661–667. doi: 10.1093/ajh/3.9.661. [DOI] [PubMed] [Google Scholar]
  8. Molina C. R., Fowler M. B., McCrory S., Peterson C., Myers B. D., Schroeder J. S., Murad F. Hemodynamic, renal and endocrine effects of atrial natriuretic peptide infusion in severe heart failure. J Am Coll Cardiol. 1988 Jul;12(1):175–186. doi: 10.1016/0735-1097(88)90371-3. [DOI] [PubMed] [Google Scholar]
  9. Murad F. Cyclic guanosine monophosphate as a mediator of vasodilation. J Clin Invest. 1986 Jul;78(1):1–5. doi: 10.1172/JCI112536. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Northridge D. B., Jardine A. G., Findlay I. N., Archibald M., Dilly S. G., Dargie H. J. Inhibition of the metabolism of atrial natriuretic factor causes diuresis and natriuresis in chronic heart failure. Am J Hypertens. 1990 Sep;3(9):682–687. doi: 10.1093/ajh/3.9.682. [DOI] [PubMed] [Google Scholar]
  11. Richards A. M., Tonolo G., McIntyre G. D., Leckie B. J., Robertson J. I. Radio-immunoassay for plasma alpha human atrial natriuretic peptide: a comparison of direct and pre-extracted methods. J Hypertens. 1987 Apr;5(2):227–236. doi: 10.1097/00004872-198704000-00015. [DOI] [PubMed] [Google Scholar]
  12. Sonnenberg J. L., Sakane Y., Jeng A. Y., Koehn J. A., Ansell J. A., Wennogle L. P., Ghai R. D. Identification of protease 3.4.24.11 as the major atrial natriuretic factor degrading enzyme in the rat kidney. Peptides. 1988 Jan-Feb;9(1):173–180. doi: 10.1016/0196-9781(88)90024-1. [DOI] [PubMed] [Google Scholar]
  13. Spirito P., Maron B. J. Influence of aging on Doppler echocardiographic indices of left ventricular diastolic function. Br Heart J. 1988 Jun;59(6):672–679. doi: 10.1136/hrt.59.6.672. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Stephenson S. L., Kenny A. J. The hydrolysis of alpha-human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11. Biochem J. 1987 Apr 1;243(1):183–187. doi: 10.1042/bj2430183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Webb D. J., Benjamin N., Allen M. J., Brown J., O'Flynn M., Cockcroft J. R. Vascular responses to local atrial natriuretic peptide infusion in man. Br J Clin Pharmacol. 1988 Sep;26(3):245–251. doi: 10.1111/j.1365-2125.1988.tb05273.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. de Bold A. J., Borenstein H. B., Veress A. T., Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1981 Jan 5;28(1):89–94. doi: 10.1016/0024-3205(81)90370-2. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES